Associations - AiRuiKa (camrelizumab)

No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	camrelizumab Sensitive: A2 - Guideline camrelizumab Sensitive : A2	camrelizumab Sensitive: A2 - Guideline camrelizumab Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab Sensitive: B - Late Trials camrelizumab Sensitive : B	camrelizumab Sensitive: B - Late Trials camrelizumab Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + camrelizumab Sensitive: C2 – Inclusion Criteria trastuzumab + camrelizumab Sensitive : C2	trastuzumab + camrelizumab Sensitive: C2 – Inclusion Criteria trastuzumab + camrelizumab Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + camrelizumab Sensitive: C2 – Inclusion Criteria trastuzumab + camrelizumab Sensitive : C2	trastuzumab + camrelizumab Sensitive: C2 – Inclusion Criteria trastuzumab + camrelizumab Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + camrelizumab Sensitive: C2 – Inclusion Criteria cetuximab + camrelizumab Sensitive : C2	cetuximab + camrelizumab Sensitive: C2 – Inclusion Criteria cetuximab + camrelizumab Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	carboplatin + camrelizumab + pemetrexed Sensitive: C3 – Early Trials carboplatin + camrelizumab + pemetrexed Sensitive : C3	carboplatin + camrelizumab + pemetrexed Sensitive: C3 – Early Trials carboplatin + camrelizumab + pemetrexed Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3
PD-L1 overexpression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 overexpression + EGFR mutation	Non Small Cell Lung Cancer	camrelizumab Resistant: C3 – Early Trials camrelizumab Resistant : C3	camrelizumab Resistant: C3 – Early Trials camrelizumab Resistant : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
TMB-H	Esophageal Cancer	TMB-H	Esophageal Cancer	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3

AiRuiKa (camrelizumab)

Associations
(85)

Associations
(85)

AiRuiKa (camrelizumab)

Associations(85)

Associations(85)

Associations
(85)

Associations
(85)